The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg (half a 15 mg tablet) per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day. Selective inhibition of the cyclooxygenase-2 (COX-2) isoenzyme, relative to COX-1, by meloxicam has been demonstrated in vitro on various cell systems: guinea pig macrophages, bovine aortic endothelial cells (for testing of COX-1 activity), mouse macrophages (for testing for COX-2 activity), and human recombinant enzymes expressed in cos-cells and in human whole blood. Reacţiile adverse care ar putea fi provocate de administrarea de Movalis şi care au apărut drept un rezultat al rapoartelor primite cu privire la administrarea produsului după punerea lui pe piaţă sunt menţionate în referinţe bibliografice. Incidenţa acestor reacţii rare este dificil de cuantificat. Se presupune că pot să apară cu o frecvenţă mai mică de 0,1%. It will not cure your condition, but it should help control pain, stiffness and swelling. It is important to keep taking your medicine even if you feel well. If you take too much (overdose) caz de supradozaj se vor lua măsurile standard de evacuare a conţinutului gastric şi terapie de susţinere, nefiind cunoscut un antidot specific. Un studiu clinic a arătat că eliminarea meloxicamului este accelerată prin utilizarea de colestiramină.

tumefactii datorate retentiei de apa/lichide (edem), inclusiv tumefactie a incheieturilor/picioarelor (edeme ale extremitatilor memebrelor) Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.Hypertension interactionElimination. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the faeces and urine. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and faeces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively. Some of the symptoms of an allergic reaction may include skin rash, itching or hives, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or troubled breathing. Deşi nu se cunosc date referitoare la Movalis, se ştie că AINS trec în laptele matern. De aceea, se recomandă evitarea administrării la femeile care alăptează. Antihipertensive (de exemplu, beta-blocante, inhibitori de angiotensin-convertază, vasodilatatoare, diuretice): Pe perioada tratamentului cu AINS s-a raportat o scădere a efectului medicamentelor antihipertensive prin inhibarea prostaglandinelor vasodilatatoare.

Use in patients with fever and infection. The pharmacological activity of Movalis in reducing inflammation and possibly fever may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.

Movalis Orodispersible Tablets is not appropriate for the treatment of patients requiring relief from acute pain.In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed. Clinical monitoring of blood pressure for patients at risk is recommended at baseline and especially during treatment initiation with Movalis Orodispersible Tablets. The typical signs and symptoms of NSAID overdose include nausea, vomiting, headache, drowsiness, blurred vision and dizziness. Rare cases of seizures, hypotension, apnoea, coma and renal failure have been reported with severe NSAID overdose. Presentation